Endocrine Resistance in Breast Cancer: Current Status and a Perspective on the Roles of MiRNAs (Review)

Overview

Journal Oncol Lett

Specialty Oncology

Date 2013 Oct 19

PMID 24137320

Citations 11

Authors

Jichun Zhou

Rongyue Teng

Qinchuan Wang

Chenpu Xu

Jufeng Guo

Chao Yuan

Jianguo Shen

Wenxian Hu

Linbo Wang

Shuduo Xie

Affiliations

Soon will be listed here.

Abstract

Current endocrine therapies for females with estrogen receptor-positive breast cancer have facilitated substantial improvements in outcomes. The effectiveness of endocrine therapy is limited by either initial resistance or acquired endocrine resistance. Multiple mechanisms responsible for endocrine resistance have been proposed, including deregulation of various components of the estrogen receptor (ER) pathway, alterations in cell cycle and cell survival signaling molecules, and the activation of escape pathways. Dysregulation of miRNA expression has been associated with experimental and clinical endocrine therapy resistance. miRNAs are pivotal to understanding the complex biological mechanism of endocrine resistance, and may serve as novel candidate predictive and prognostic surrogates and therapeutic targets. This review focuses on current progress concerning the roles of miRNAs in endocrine resistance, and discusses the challenges and opportunities for implementing miRNA-based assays and treatment for patients with endocrine-resistant breast cancer.

Citing Articles

Facilitates Endocrine Resistance in Breast Cancer Through / Axis: Comprehensive Analysis of mRNA-miRNA-lncRNA Network.

Zhang M, Wu K, Zhang P, Qiu Y, Bai F, Chen H Int J Gen Med. 2021; 14:4653-4663.

PMID: 34434057 PMC: 8380629. DOI: 10.2147/IJGM.S320998.

Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer.

Watanabe T, Oba T, Tanimoto K, Shibata T, Kamijo S, Ito K PLoS One. 2021; 16(6):e0252822.

PMID: 34101751 PMC: 8186817. DOI: 10.1371/journal.pone.0252822.

Regulation of tamoxifen sensitivity by the PLAC8/MAPK pathway axis is antagonized by curcumin-induced protein stability change.

Mao M, Hu D, Yang J, Chen Y, Zhang X, Shen J J Mol Med (Berl). 2021; 99(6):845-858.

PMID: 33611659 PMC: 8164584. DOI: 10.1007/s00109-021-02047-5.

HMGB1 is a key factor for tamoxifen resistance and has the potential to predict the efficacy of CDK4/6 inhibitors in breast cancer.

Zhang H, Wang J, Li J, Zhou X, Yin L, Wang Y Cancer Sci. 2021; 112(4):1603-1613.

PMID: 33453094 PMC: 8019207. DOI: 10.1111/cas.14813.

Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.

Li D, Ji H, Niu X, Yin L, Wang Y, Gu Y Cancer Sci. 2019; 111(1):47-58.

PMID: 31710162 PMC: 6942430. DOI: 10.1111/cas.14230.

References

Lee R, Ambros V . An extensive class of small RNAs in Caenorhabditis elegans. Science. 2001; 294(5543):862-4. DOI: 10.1126/science.1065329. View

Mueller D, Bosserhoff A . Role of miRNAs in the progression of malignant melanoma. Br J Cancer. 2009; 101(4):551-6. PMC: 2736818. DOI: 10.1038/sj.bjc.6605204. View

Cortes-Sempere M, de Caceres I . microRNAs as novel epigenetic biomarkers for human cancer. Clin Transl Oncol. 2011; 13(6):357-62. DOI: 10.1007/s12094-011-0668-z. View

Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C . Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem. 2011; 286(49):42292-42302. PMC: 3234972. DOI: 10.1074/jbc.M111.270926. View

Tian W, Chen J, He H, Deng Y . MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clin Transl Oncol. 2012; 15(5):335-42. DOI: 10.1007/s12094-012-0929-5. View

Ma L, Teruya-Feldstein J, Weinberg R . Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007; 449(7163):682-8. DOI: 10.1038/nature06174. View

Negrini M, Calin G . Breast cancer metastasis: a microRNA story. Breast Cancer Res. 2008; 10(2):203. PMC: 2397516. DOI: 10.1186/bcr1867. View

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Cittelly D, Das P, Salvo V, Fonseca J, Burow M, Jones F . Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis. 2010; 31(12):2049-57. PMC: 2994280. DOI: 10.1093/carcin/bgq192. View

10.

Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S . MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009; 361(15):1437-47. PMC: 2786938. DOI: 10.1056/NEJMoa0901282. View

11.

Osborne C . Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer. Endocr Relat Cancer. 2000; 6(2):271-6. DOI: 10.1677/erc.0.0060271. View

12.

Iorio M, Ferracin M, Liu C, Veronese A, Spizzo R, Sabbioni S . MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005; 65(16):7065-70. DOI: 10.1158/0008-5472.CAN-05-1783. View

13.

Miller T, Ghoshal K, Ramaswamy B, Roy S, Datta J, Shapiro C . MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem. 2008; 283(44):29897-903. PMC: 2573063. DOI: 10.1074/jbc.M804612200. View

14.

Osborne C, Pippen J, Jones S, Parker L, Ellis M, Come S . Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002; 20(16):3386-95. DOI: 10.1200/JCO.2002.10.058. View

15.

Musgrove E, Sutherland R . Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer. 2009; 9(9):631-43. DOI: 10.1038/nrc2713. View

16.

Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C . let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007; 131(6):1109-23. DOI: 10.1016/j.cell.2007.10.054. View

17.

Hossain A, Kuo M, Saunders G . Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol. 2006; 26(21):8191-201. PMC: 1636750. DOI: 10.1128/MCB.00242-06. View

18.

Bartel D, Chen C . Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet. 2004; 5(5):396-400. DOI: 10.1038/nrg1328. View

19.

Ventura A, Jacks T . MicroRNAs and cancer: short RNAs go a long way. Cell. 2009; 136(4):586-91. PMC: 3910108. DOI: 10.1016/j.cell.2009.02.005. View

20.

Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N . Serum microRNAs are promising novel biomarkers. PLoS One. 2008; 3(9):e3148. PMC: 2519789. DOI: 10.1371/journal.pone.0003148. View